Cargando…

Participant demographics reported in "Table 1" of randomised controlled trials: a case of "inverse evidence"?

INTRODUCTION: Data supporting external validity of trial results allows clinicians to assess the applicability of a study's findings to their practice population. Socio-economic status (SES) of trial participants may be critical to external validity given the relationship between social and eco...

Descripción completa

Detalles Bibliográficos
Autores principales: Furler, John, Magin, Parker, Pirotta, Marie, van Driel, Mieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3379950/
https://www.ncbi.nlm.nih.gov/pubmed/22429574
http://dx.doi.org/10.1186/1475-9276-11-14
_version_ 1782236266801135616
author Furler, John
Magin, Parker
Pirotta, Marie
van Driel, Mieke
author_facet Furler, John
Magin, Parker
Pirotta, Marie
van Driel, Mieke
author_sort Furler, John
collection PubMed
description INTRODUCTION: Data supporting external validity of trial results allows clinicians to assess the applicability of a study's findings to their practice population. Socio-economic status (SES) of trial participants may be critical to external validity given the relationship between social and economic circumstances and health. We explored how this is documented in reports of RCTs in four major general medical journals. METHODS: The contents lists of four leading general medical journals were hand searched to identify 25 consecutive papers reporting RCT results in each journal (n = 100). Data on demographic characteristics were extracted from each paper's Table 1 only (or equivalent). RESULTS: Authors infrequently reported key demographic characteristics relating to SES of RCT participants. Age and gender of participants were commonly reported. Less than 10% reported occupational group, employment status, income or area based measures of disadvantage. CONCLUSIONS: Without adequate reporting of key indicators of SES in trial participants it is unclear if lower SES groups are under-represented. If such groups are systematically under-recruited into trials, this may limit the external validity and applicability of study findings to these groups. This is in spite of the higher health-care need in more disadvantaged populations. Under-representation of low SES groups could underestimate the reported effect of an intervention for those with a higher baseline risk. The marginal benefit identified in a trial with poor or no representation of lower SES participants could significantly underestimate the potential benefit to a low SES community. More transparency in this reporting and greater attention to the impact of SES on intervention outcomes in clinical trials is needed. This could be considered in the next revision of the CONSORT statement.
format Online
Article
Text
id pubmed-3379950
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33799502012-06-21 Participant demographics reported in "Table 1" of randomised controlled trials: a case of "inverse evidence"? Furler, John Magin, Parker Pirotta, Marie van Driel, Mieke Int J Equity Health Research INTRODUCTION: Data supporting external validity of trial results allows clinicians to assess the applicability of a study's findings to their practice population. Socio-economic status (SES) of trial participants may be critical to external validity given the relationship between social and economic circumstances and health. We explored how this is documented in reports of RCTs in four major general medical journals. METHODS: The contents lists of four leading general medical journals were hand searched to identify 25 consecutive papers reporting RCT results in each journal (n = 100). Data on demographic characteristics were extracted from each paper's Table 1 only (or equivalent). RESULTS: Authors infrequently reported key demographic characteristics relating to SES of RCT participants. Age and gender of participants were commonly reported. Less than 10% reported occupational group, employment status, income or area based measures of disadvantage. CONCLUSIONS: Without adequate reporting of key indicators of SES in trial participants it is unclear if lower SES groups are under-represented. If such groups are systematically under-recruited into trials, this may limit the external validity and applicability of study findings to these groups. This is in spite of the higher health-care need in more disadvantaged populations. Under-representation of low SES groups could underestimate the reported effect of an intervention for those with a higher baseline risk. The marginal benefit identified in a trial with poor or no representation of lower SES participants could significantly underestimate the potential benefit to a low SES community. More transparency in this reporting and greater attention to the impact of SES on intervention outcomes in clinical trials is needed. This could be considered in the next revision of the CONSORT statement. BioMed Central 2012-03-19 /pmc/articles/PMC3379950/ /pubmed/22429574 http://dx.doi.org/10.1186/1475-9276-11-14 Text en Copyright ©2012 Furler et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Furler, John
Magin, Parker
Pirotta, Marie
van Driel, Mieke
Participant demographics reported in "Table 1" of randomised controlled trials: a case of "inverse evidence"?
title Participant demographics reported in "Table 1" of randomised controlled trials: a case of "inverse evidence"?
title_full Participant demographics reported in "Table 1" of randomised controlled trials: a case of "inverse evidence"?
title_fullStr Participant demographics reported in "Table 1" of randomised controlled trials: a case of "inverse evidence"?
title_full_unstemmed Participant demographics reported in "Table 1" of randomised controlled trials: a case of "inverse evidence"?
title_short Participant demographics reported in "Table 1" of randomised controlled trials: a case of "inverse evidence"?
title_sort participant demographics reported in "table 1" of randomised controlled trials: a case of "inverse evidence"?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3379950/
https://www.ncbi.nlm.nih.gov/pubmed/22429574
http://dx.doi.org/10.1186/1475-9276-11-14
work_keys_str_mv AT furlerjohn participantdemographicsreportedintable1ofrandomisedcontrolledtrialsacaseofinverseevidence
AT maginparker participantdemographicsreportedintable1ofrandomisedcontrolledtrialsacaseofinverseevidence
AT pirottamarie participantdemographicsreportedintable1ofrandomisedcontrolledtrialsacaseofinverseevidence
AT vandrielmieke participantdemographicsreportedintable1ofrandomisedcontrolledtrialsacaseofinverseevidence